VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMW 2019 | Founding precision therapy for 1q-amplified multiple myeloma

Romanos Sklavenitis-Pistofidis
IMW 2019
Rare Diseases Waldenström’s Macroglobulinemia

Romanos Sklavenitis-Pistofidis, MD Dana-Farber Cancer Institute, Boston, MA, discusses founding precision therapy for 1q-amplified multiple myeloma at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Romanos Sklavenitis-Pistofidis

3:38
Identifying immune biomarkers of progression in patients with HR-SMM treated with immunotherapy
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
3:25
Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
3:23
Progression risk stratification of asymptomatic WM
Romanos Sklavenitis-Pistofidis
6:33
Risk stratification model for asymptomatic Waldenström’s macroglobulinemia
Romanos Sklavenitis-Pistofidis • 1 Nov 2022

Related Videos

3:23
Progression risk stratification of asymptomatic WM
Romanos Sklavenitis-Pistofidis
1:49
CXCR4 in Waldenström’s macroglobulinemia
Zachary Hunter
1:03
LentiGlobin BB305 for β-Thalassemia
Christian Chabannon
6:57
Key updates in MPNs from ASH 2018
Claire Harrison

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals